-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Relapsed/refractory multiple myeloma (RRMM) has a high disease burden and complications related to the refractory of previous treatment lines, severe pain and fatigue symptoms, and impaired physical and emotional functions, which are related to the health-related quality of life of RRMM patients (HRQoL) decrease is closely related
Relapsed/refractory multiple myeloma (RRMM) has a high disease burden and complications related to the refractory of previous treatment lines, severe pain and fatigue symptoms, and impaired physical and emotional functions, which are related to the health-related quality of life of RRMM patients (HRQoL) decrease is closely related
Melflufen is a first-class peptide drug conjugate (PDC) that targets aminopeptidase to rapidly release alkylating agents in tumor cells.
Meflufen plus dexamethasone is used in RRMM patients who have previously received at least two treatment regimens, including immunomodulators and PI, and pomalidomide and/or an anti-CD38 mAb
Figure 1: EQ-5D-3L change from baseline and the proportion of impaired patients assessed by the EQ-5D-3L domain during the treatment cycle
Figure 1: EQ-5D-3L change from baseline and the proportion of impaired patients assessed by the EQ-5D-3L domain during the treatment cycle
Figure 2: The average change in LS in EORTC QLQ-C30 compared to baseline
Figure 2: The average change in LS in EORTC QLQ-C30 compared to baseline
Figure 3: Proportion of patients with a significant improvement from baseline on the EORTC QLQ-C30 scale throughout the treatment cycle
Figure 3: Proportion of patients with a significant improvement from baseline on the EORTC QLQ-C30 scale throughout the treatment cycle
Figure 4: EORTC QLQ-C30 Global Health Status/QoL and Pain Scale to determine the time of deterioration analysis
4：EORTC QLQ-C30 /QoL
8 ，/QoL、、、
，， RRMMHRQoL，
Larocca, A.
Larocca, A.
, Leleu, X.
, Touzeau, C.
, Bladé, J.
, Paner, A.
, Mateos, M.
-V.
, Cavo, M.
, Maisel, C.
, Alegre, A.
, Oriol, A.
, Raptis, A.
, Rodriguez-Otero, P.
, Mazumder, A.
, Laubach, J.
, Nadeem, O.
, Sandberg, A.
, Orre, M.
, Torrång, A.
, Bakker, NA and Richardson , PG (2021), Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol.
https://doi.
org/10.
1111/bjh.
17887
Leave a message here
